关注
Nadeem Riaz
标题
引用次数
引用次数
年份
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
31852019
Tumor and microenvironment evolution during immunotherapy with nivolumab
N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba, JS Sims, FS Hodi, ...
Cell 171 (4), 934-949. e16, 2017
17712017
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ...
Science 359 (6375), 582-587, 2018
10222018
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
VP Balachandran, M Łuksza, JN Zhao, V Makarov, JA Moral, R Remark, ...
Nature 551 (7681), 512-516, 2017
10122017
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a …
C Luchini, F Bibeau, MJL Ligtenberg, N Singh, A Nottegar, T Bosse, ...
Annals of Oncology 30 (8), 1232-1243, 2019
8082019
Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a …
B O'Sullivan, SH Huang, J Su, AS Garden, EM Sturgis, K Dahlstrom, ...
The Lancet Oncology 17 (4), 440-451, 2016
7712016
The head and neck cancer immune landscape and its immunotherapeutic implications
R Mandal, Y Şenbabaoğlu, A Desrichard, JJ Havel, MG Dalin, N Riaz, ...
JCI insight 1 (17), 2016
6982016
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
M Łuksza, N Riaz, V Makarov, VP Balachandran, MD Hellmann, ...
Nature 551 (7681), 517-520, 2017
6012017
Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
R Mandal, RM Samstein, KW Lee, JJ Havel, H Wang, C Krishna, ...
Science 364 (6439), 485-491, 2019
4622019
Mitochondrial DNA copy number variation across human cancers
E Reznik, ML Miller, Y Şenbabaoğlu, N Riaz, J Sarungbam, SK Tickoo, ...
elife 5, e10769, 2016
4562016
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy
G Goh, T Walradt, V Markarov, A Blom, N Riaz, R Doumani, K Stafstrom, ...
Oncotarget 7 (3), 3403, 2016
3812016
Immunogenic neoantigens derived from gene fusions stimulate T cell responses
W Yang, KW Lee, RM Srivastava, F Kuo, C Krishna, D Chowell, ...
Nature medicine 25 (5), 767-775, 2019
3202019
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
BH Lok, EE Gardner, VE Schneeberger, A Ni, P Desmeules, N Rekhtman, ...
Clinical Cancer Research 23 (2), 523-535, 2017
2972017
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
LGT Morris, N Riaz, A Desrichard, Y Şenbabaoğlu, AA Hakimi, V Makarov, ...
Oncotarget 7 (9), 10051, 2016
2932016
Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma
S McBride, E Sherman, CJ Tsai, S Baxi, J Aghalar, J Eng, WI Zhi, ...
Journal of Clinical Oncology 39 (1), 30-37, 2021
2852021
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
C Valero, M Lee, D Hoen, K Weiss, DW Kelly, PS Adusumilli, PK Paik, ...
Nature communications 12 (1), 729, 2021
2602021
Integrated genomic analysis of Hürthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes
I Ganly, V Makarov, S Deraje, YY Dong, E Reznik, V Seshan, ...
Cancer cell 34 (2), 256-270. e5, 2018
2432018
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
D Chowell, C Krishna, F Pierini, V Makarov, NA Rizvi, F Kuo, LGT Morris, ...
Nature medicine 25 (11), 1715-1720, 2019
2412019
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
YP Chen, YQ Wang, JW Lv, YQ Li, MLK Chua, QT Le, N Lee, AD Colevas, ...
Annals of Oncology 30 (1), 68-75, 2019
2282019
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes
N Riaz, P Blecua, RS Lim, R Shen, DS Higginson, N Weinhold, L Norton, ...
Nature communications 8 (1), 857, 2017
2172017
系统目前无法执行此操作,请稍后再试。
文章 1–20